Quanterix Corporation · NASDAQ:QTRX
Quanterix — J.P. Morgan Healthcare Conference 2024
23 slides from Quanterix's conference presentation, Jan 10, 2024
Slide 1: J.P. Morgan Healthcare Conference 2024
„ J.P. Morgan Healthcare Conference 2024 Masoud Toloue, CEO January 10, 2024
Slide 2: Forward-Looking Statements & Non-GAAP Financial Measures
Forward-Looking Statements & Non-GAAP Financial Measures This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," "anticipate," "estimate," "intend" and similar expressions (as wel
Slide 3: Our Mission: Create the tools enabling discovery and better health
OUR MISSION Create the tools enabling discovery and better health $121M $18M Unmatched Technology Revenue1 Cash burn1 >950 Instruments installed High 50%’s Appr. 50% GAAP Non-GAAP Gross Margin2 Gross Margin2 Early penetration in multi-billion diagnostics CLIA lab running validated neuro LDTs 550+ 2,
Slide 4: Simoa detects biomarkers unmeasurable by other technology
Simoa detects biomarkers unmeasurable by other technology ng/mL ELISA 900x pg/mL Sensitivity increase Other protein detection fg/mL technology ag/mL Simoa Today 4
Slide 5: Simoa: Surpassing detection limits to deliver exquisite sensitivity
Surpassing detection limits to deliver exquisite sensitivity Traditional ® Analog ELISA assay Simoa Digital Millions of molecules needed to Single molecule needed to reach detection limit reach detection limit SUBSTRATE 0 pM 10 pM 0 aM 3.5 aM 350 aM 3.5 fM 5
Slide 6: Catching disease early
Catching disease early Simoa enables health-care… …versus today's sick-care management STAGE OF INTERVENTION HEALTHY LATE DISEASE Non-invasive Non-invasive Invasive Earliest stage detection Competitors Technologies 6
Slide 7: Completed corporate transformation to maximize full potential of our capabilities
Completed corporate transformation to maximize full potential of our capabilities and build a strong foundation in preparation for future growth 7
Slide 8: Consistent execution while driving broad transformation
Consistent execution while driving broad transformation Non-GAAP Cash Revenue1 Gross Margin2 Burn1 Highly scaled production 2023 lines $121M Appr. 50% $18M Accelerated innovation rates Up Improved Reduced 15% 1200 bps >3x Strong foundation for future growth 2022 $105.5M 38% $58M 1. Preliminary unaud
Slide 9: Delivering an efficient operating framework
Delivering an efficient operating framework Improvement of 50% Improvement of 300% Increase of 80% in 6 quarters in 6 quarters in 6 quarters Testing Scale Manufacturability Studies >0.75M1 tests >4M1 tests >45 ongoing per year per year studies with capacity to with capacity to supported in increase
Slide 10: As the foundation for a ramping innovation rate in 2024
As the foundation for a ramping innovation rate in 2024 Prior 2 years 2023 2024 and beyond Launched 0 Launched >20 assays a year new assays 5 new assays Develop platform One LDT Test One LDT Test (Plexity & automation) IVD launch Harmonized processes driving rapid menu expansion Assay development ti
Slide 11: Quanterix to advance the decade of Neuro
With an efficient operating framework and a higher than ever innovation rate Quanterix to advance the decade of Neuro 11
Slide 12: The decade of Neuro
The decade of Neuro Increasing Emerging pipeline Demographic Need >20 large biopharma Projected 139M AD cases1 by 2050 running >120 CNS programs2 Extensively validated blood biomarkers Accelerator Lab indicators Supporting FDA accelerated approval 47 neuro trials ongoing with Quanterix (e.g. NfL) Ap
Slide 13: Simoa biomarkers continue to enable therapy approvals
Simoa biomarkers continue to enable therapy approvals Failed Phase Quanterix NfL FDA accelerated 3 study biomarker approval 108-subject study: provides evidence to NfL provides enough basis Clinical measures alone did show reduction in plasma for a conditional approval not show benefit neurofilament
Slide 14: Growing trials and approved therapies
Growing trials and approved therapies >120 biopharma CNS clinical-stage programs of which 24 programs 4 drugs* approved focused specifically on AD 2 drugs* All 4 fueled by Long runway of continued approved double-digit growth in research ✓ Revenue crossing $100M ✓ >45 active projects Academic Focus
Slide 15: Alzheimer's Disease as the core of our Diagnostics focus
Multiple ongoing With studies in Neurology ✓ AD ✓ Parkinson Alzheimer's Disease ✓ ALS ✓ TBI as the core of our ✓ MS ✓ Neuropsychology Diagnostics focus 15
Slide 16: Alzheimer's disease burden
Alzheimer's - 1 in 9 people aged 65 and older in the US has it >55M globally living with Alzheimer’s Every 3 seconds US$1.3 trillion someone in the world global societal cost of By 2050 projected to develops Alzheimer’s dementia in 2019 rise to 139M Mortality in the US more than breast and prostate
Slide 17: Detecting early with Simoa will impact quality of life
Detecting early with Simoa will impact quality of life Meets NIA-AA … to address a Revised Criteria ... significant need p-Tau 217 75% people for Diagnosis and Staging not diagnosed of Alzheimer’s Disease globally Source: National Institute on Aging (NIA) and Alzheimer Disease International (https:/
Slide 18: Offering a test for all patients - LucentAD p-Tau 217
Offering a test for all patients - LucentAD p-Tau 217 Alzheimer's Disease Continuum p-Tau 217 EARLY STAGE LATE STAGE Earliest Scalable Highly Stage workflow Accurate ✓ 93% Accuracy ✓ 98% Specificity ✓ 90% Sensitivity Only test meeting the NIA-AA criteria for diagnosing and staging of AD The LucentAD
Slide 19: Quanterix best positioned for Alzheimer's detection today
Quanterix best positioned for Alzheimer's detection today Non- Enabled DX lab DX lab Mass Spectrometry Chemiluminescence Quantitative range High High Limited in clinical cohorts Detect p-Tau 217 Yes Yes No Simoa technology (Meet NIA-AA guidelines) uniquely suited for Cost of test Low High Low buildi
Slide 20: Unique power of ultra-sensitivity
And uniquely set to lead the decade of Neuro Tomorrow Unique power of ultra-sensitivity Today Access Menu Workflow Affordability CSF and Blood-based markers >950 Installed Single and Multi- Low cost DBS base marker Aβ 40/42, NfL, IVD, Multi-marker Dried Blood Spot p-Tau 181, (in development) (in dev
Slide 21: With a clear focus to maximize access to patients
With a clear focus to maximize access to patients Allocating capital to execute commercial adoption Reimbursement: Submitted for CPT code (expected in 2024) Over $20M of capital ‘ allocated for next 2 years to FDA: advance AD Breakthrough designation received for 2 (expected 3rd in 2024) Diagnostics
Slide 22: A diversified portfolio geared to beat industry headwinds
A diversified portfolio that is geared to beat industry headwinds with recent transformation and multiple growth drivers Diversified Indexed to well Growing portfolio funded pharma trials Mitigates macro headwinds Several mid to late-stage While Dx ramps, continued in Life Science tools space progra
Slide 23: Built to lead neuro decade
Built to lead neuro decade Strong Double digit Non-GAAP GM2 of Strong Balance Sheet top-line growth1 appr. 50% >$300M1 in net cash Results Improvement of 1200 bps Annual cash burn1 down by >3x Lab Services Manufacturing capacity Innovation rate Operational >4M tests per year >20 assays per year capa